Our passion for patients in need fuels our dedication to fill the therapeutic void with potential for the future. With RNA as the basis of our discovery platform, we are able to bring therapeutic options to patients who otherwise would have limited or no options.
Ionis has discovered and developed six currently marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases.
For more information about WAINUA and US prescribing information, visit WAINUA.com.
For more information about QALSODY and US prescribing information, visit QALSODY.com.
For more information about SPINRAZA and US prescribing information, visit SPINRAZA.com.
For TEGSEDI prescribing information in the EU, please visit ema.europa.eu/en/medicines/human/EPAR/tegsedi.
Medicine not available in the US.
For WAYLIVRA prescribing information in the EU, please visit ema.europa.eu/en/medicines/human/EPAR/waylivra.
Medicine not available in the US.
US-ABR-2400001 v3 02/2025
View our Clinical Pipeline
We are relentlessly pursuing the innovations of tomorrow with our broad and diverse pipeline of potential first or best-in-class investigational therapies designed to treat a range of diseases. Learn more about our pipeline.
For more information about TRYNGOLZA™ and U.S. prescribing information, visit TRYNGOLZA.com.
WAINUA™ is co-commercialized with AstraZeneca in the U.S. For more information about WAINUA and U.S. prescribing information, visit WAINUA.com.
QALSODY® is marketed by Biogen. For more information about QALSODY and U.S. prescribing information, visit QALSODY.com.
SPINRAZA® is marketed by Biogen. For more information about SPINRAZA and U.S. prescribing information, visit SPINRAZA.com.
TEGSEDI® is distributed by SOBI. For TEGSEDI prescribing information in the EU, please visit ema.europa.eu/en/medicines/human/EPAR/tegsedi.
WAYLIVRA™ is distributed by SOBI. For WAYLIVRA prescribing information in the EU, please visit ema.europa.eu/en/medicines/human/EPAR/waylivra.
